NASDAQ · Biotechnology
FULC (FULC) Stock
$3.73
+0.13%
NASDAQ: FULC
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Fulcrum Therapeutics (FULC) Stock Fair Value Moves Lower After Pociredir Exit
Simply Wall St. · Jun 27, 2026
A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring
Simply Wall St. · Jun 5, 2026
Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks · Jun 5, 2026
FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End
Zacks · Jun 3, 2026
JPMorgan Downgrades Fulcrum Therapeutics to Underweight From Overweight
MT Newswires · Jun 3, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held3.83%
Institutions Held126.06%
Institutions Float Held131.08%
Peer Comparison
About FULC
FULC is led by CEO Alexander C. Sapir, employs 45 people, headquartered in US, publicly traded since 2019.
FULC stock trades at $3.73 with a market capitalization of $201.56M. The stock is valued at a price-to-earnings (P/E) ratio of -5.17, price-to-book of 0.95, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.83 and $15.74, and currently trades 76.3% below its 52-week high.
On profitability, FULC generates a return on equity (ROE) of -21.49%, return on capital employed of -24.36%, an operating margin of 0.00%, a net profit margin of 0.00%.